H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317(13), 1338–1348 (2017)

Article  PubMed  PubMed Central  Google Scholar 

A. Miranda-Filho, J. Lortet-Tieulent, F. Bray, B. Cao, S. Franceschi, S. Vaccarella et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225–234 (2021)

Article  PubMed  Google Scholar 

C.D. Seib, J.A. Sosa, Evolving understanding of the epidemiology of thyroid cancer. Endocrinol. Metab. Clin. North Am. 48(1), 23–35 (2019)

Article  PubMed  Google Scholar 

M. Aashiq, D.A. Silverman, S. Na’ara, H. Takahashi, M. Amit, Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel) 11(9), 1382 (2019)

Article  CAS  PubMed  Google Scholar 

Z.Z. Mu, X. Zhang, Y.S. Lin, Identification of radioactive iodine refractory differentiated thyroid cancer. Chonnam Med J. 55(3), 127–135 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Lorusso, E. Minaldi, G. Esposito, P. Piaggi, V. Bottici, S. Brogioni et al. Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features. J. Endocrinol. Invest 46(10), 2165–2173 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)

Article  PubMed  PubMed Central  Google Scholar 

J.J. Teunissen, D.J. Kwekkeboom, P.P. Kooij, W.H. Bakker, E.P. Krenning, Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J. Nucl. Med. 46(Suppl 1), 107S–114SS (2005)

CAS  PubMed  Google Scholar 

A. Klagge, K. Krause, K. Schierle, F. Steinert, H. Dralle, D. Fuhrer, Somatostatin receptor subtype expression in human thyroid tumours. Horm. Metab. Res 42(4), 237–240 (2010)

Article  CAS  PubMed  Google Scholar 

H. Pisarek, T. Stepień, R. Kubiak, E. Borkowska, M. Pawlikowski, Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res 2(1), 1 (2009)

Article  PubMed  PubMed Central  Google Scholar 

S. Sancak, A. Hardt, J. Singer, G. Klöppel, F.T. Eren, B.M. Güllüoglu et al. Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves’ disease. Thyroid 20(5), 505–511 (2010)

Article  CAS  PubMed  Google Scholar 

G. Treglia, G. Rindi, V. Rufini, Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. Hormones (Athens) 11(3), 230–232 (2012)

Article  PubMed  Google Scholar 

T. Lincke, J. Singer, R. Kluge, O. Sabri, R. Paschke, Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid 19(4), 381–389 (2009)

Article  CAS  PubMed  Google Scholar 

G. Treglia, A. Tamburello, L. Giovanella, Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens) 16(4), 362–372 (2017)

PubMed  Google Scholar 

J.D. Kohlenberg, A. Panda, G.B. Johnson, M.R. Castro, Radiologic and clinicopathologic characteristics of thyroid nodules with focal 68Ga-DOTATATE PET activity. Nucl. Med. Commun. 42(5), 510–516 (2021)

Article  CAS  PubMed  Google Scholar 

J. Kunikowska, R. Matyskiel, P. Pawliszak, A. Zemczak, D. Pawlak, M. Plazinska et al. Analysis of additional 68Ga-DOTATATE thyroid uptake in patients with neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 40, S479 (2013)

Google Scholar 

T. Lincke, G. Orschekowski, J. Singer, O. Sabri, R. Paschke, Increased Gallium-68 DOTATOC uptake in normal thyroid glands. Horm. Metab. Res. 43(4), 282–286 (2011)

Article  CAS  PubMed  Google Scholar 

P. Nockel, C. Millo, X. Keutgen, J. Klubo-Gwiezdzinska, J. Shell, D. Patel et al. The rate and clinical significance of incidental thyroid uptake as detected by Gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid 26(6), 831–835 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Singer, T. Lincke, O. Sabri, R. Paschke, Ga-68-Dotatoc P.E.T. detects a basal somatostatin receptor expression in normal, nodular, and goitrous thyroid glands. Thyroid 17, S102 (2007)

Google Scholar 

M.C. Kreissl, F.A. Verburg, M.C. Hategan, R. Lorenz, J. Biko, I. Israel et al. Assessment of somatostatin receptor expression in advanced follicular thyroid cancer using Ga-68-DOTATOC-PET. Eur. J. Nucl. Med. Mol. Imaging 37, S290 (2010)

Google Scholar 

D. Putzer, A.K. Ross, M.G. Abriel, D. Kendler, G. Dobrozemsky, R. Bale et al. 68Ga-DOTA-Tyr3-octreotide PET in thyroid cancer patients compared to 18F-FDG-PET and radioiodine-avidity. Eur. J. Nucl. Med. Mol. Imaging 37, S214 (2010)

Google Scholar 

E. Demirci, L. Kabasakal, M. Ocak, A. Aygun, M. Halac, B. Kanmaz, Evaluation of 68Ga-DOTA-TATE and68Ga-DOTA-NOC PET/CT in patients with differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 39, S404 (2012)

Google Scholar 

M. Ocak, E. Demirci, L. Kabasakal, A. Aygun, R.O. Tutar, A. Araman et al. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl. Med. Commun. 34(11), 1084–1089 (2013)

Article  CAS  PubMed  Google Scholar 

S. Li, F. Wang, X. Yao, R. Liu, L. Zhang, 68Ga-DOTA-NOC and 18F-FDG PET/CT for the diagnosis of Iodine-refractory differentiated thyroid cancer : Pilot studies. Eur. J. Nucl. Med. Mol. Imaging 44(2), S650–S651 (2017)

Google Scholar 

B. Vatankulu, B. Akovali, S. Saǧer, M. Halaç, L. Kabasakal, K. Sönmezoǧlu, 68Ga-DOTA-TATE PET-CT in differentiated thyroid cancer patients: Comparison with 18F-FDG PET-CT. Eur. J. Nucl. Med. Mol. Imaging 43(1), S223 (2016)

Google Scholar 

I. Binse, T.D. Poeppel, M. Ruhlmann, S. Ezziddin, R. Görges, A. Sabet et al. 68Ga-DOTATOC PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J. Nucl. Med. 57(10), 1512–1517 (2016)

Article  CAS  PubMed  Google Scholar 

L.S. Almeida, M.C. Araújo, D.E. Zantut-Wittmann, L.V. Assumpção, T.F. Souza, C.M. Silva et al. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study. Nucl. Med. Commun. 39(5), 441–450 (2018)

Article  CAS  PubMed  Google Scholar 

M. Theodoropoulou, G.K. Stalla, Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 34(3), 228–252 (2013)

Article  CAS  PubMed  Google Scholar 

A. Gillis, R. Zheng-Pywell, C. McLeod, D. Wang, J.M. Ness, R. Guenter et al. Somatostatin receptor type 2 and thyroid-stimulating hormone receptor expression in oncocytic thyroid neoplasms: implications for prognosis and treatment. Mod. Pathol. 36(12), 100332 (2023)

Article  PubMed  Google Scholar 

S. Singh, R.K. Somvanshi, V. Panda, U. Kumar, Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism. Endocrine 70(1), 92–106 (2020)

Article  CAS  PubMed  Google Scholar 

D.M. Carmona Matos, S. Jang, B. Hijaz, A.W. Chang, R.V. Lloyd, H. Chen et al. Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers. Surgery 165(1), 64–68 (2019)

Article  PubMed  Google Scholar 

Y. Sanli, I. Garg, A. Kandathil, T. Kendi, M.J.B. Zanetti, S. Kuyumcu et al. Neuroendocrine tumor diagnosis and management. AJR Am. J. Roentgenol. 211(2), 267–277 (2018)

Article  Google Scholar 

J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen et al. Phase 3 Trial of. N. Engl. J. Med. 376(2), 125–135 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Oliván-Sasot, M. Falgás-Lacueva, J. García-Sánchez, V. Vera-Pinto, C. Olivas-Arroyo, P. Bello-Arques, Use of. Rev. Esp. Med Nucl. Imagen Mol. 36(2), 116–119 (2017)

PubMed  Google Scholar 

S. Gubbi, M. Al-Jundi, J. Del Rivero, A. Jha, M. Knue, J. Zou et al. Case report: primary hypothyroidism associated with lutetium 177-DOTATATE therapy for metastatic paraganglioma. Front Endocrinol. (Lausanne) 11, 587065 (2020)

Article  PubMed  Google Scholar